A carregar...
Systemic inflammation is a determinant of outcomes of CD40 agonist–based therapy in pancreatic cancer patients
Agonistic anti-CD40 monoclonal antibody (mAb) therapy in combination with chemotherapy (chemoimmunotherapy) shows promise for the treatment of pancreatic ductal adenocarcinoma (PDA). To gain insight into immunological mechanisms of response and resistance to chemoimmunotherapy, we analyzed blood sam...
Na minha lista:
| Publicado no: | JCI Insight |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Clinical Investigation
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8021099/ https://ncbi.nlm.nih.gov/pubmed/33497362 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.145389 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|